Results of prospective randomized phase III study of the EBMT (Ricmac trial) dose-reduced versus standard conditioning followed by allogeneic stem cell transplantation for patients with myelodysplastic syndrome

(European Society for Blood and Marrow Transplantation) The EBMT announces the results from the RICMAC trial, published in the Journal of Clinical Oncology on Tuesday 2 May 2017. These results show evidence that reduced-intensity conditioning regimen (RIC) result in at least a 2-year relapse-free survival and overall survival similar to standard conditioning regimen (MAC) in patients with MDS or secondary acute AML.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news